文献速递肝病消化道出血

肝硬化凝血障碍患者输注新鲜冰冻血浆对常规凝血试验及血栓调节蛋白修饰凝血酶生成的影响

Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.
PubMed 文献 · J Hepatol · 2019-09-16

该前瞻性研究纳入53例接受标准剂量新鲜冰冻血浆(FFP)治疗的肝硬化伴凝血障碍患者,评估输注后凝血酶生成变化。结果显示FFP使血栓调节蛋白修饰的内源性凝血酶潜能(ETP-TM)仅提高5.7%,且34%患者ETP-TM反而下降;常规凝血指标改善但少数降至正常。提示FFP对凝血酶生成的改善有限,预防或治疗出血的获益不明确。

要点

  • FFP输注后ETP-TM仅提高5.7%,34%患者ETP-TM反而下降。
  • 输注前94%患者ETP-TM正常或升高,低ETP-TM者无出血。
  • 常规凝血指标改善,但少数患者INR/PT比值降至1.5以下。

核心结论

  • FFP输注可增强凝血酶生成并改善常规凝血试验至正常值,但仅见于有限数量患者。
  • 34%的患者输注后凝血酶生成轻度下降。
  • 以预防或治疗出血为目的的FFP输注可能带来固有风险和费用而无明确获益。

研究设计与样本

  • 前瞻性研究,连续纳入53例接受标准剂量FFP治疗的肝硬化伴凝血障碍患者。
  • FFP用于治疗出血和/或侵入性操作前,纳入条件为INR/PT比值≥1.5。
  • 主要终点为输注后血栓调节蛋白修饰的内源性凝血酶潜能(ETP-TM)改善。

主要发现

  • FFP使ETP-TM提高5.7%,从973(731-1258)升至1028(885-1343 nM×min),p=0.019。
  • 输注前94%患者ETP-TM正常或升高,仅1例(1.9%)输注后ETP-TM恢复正常范围。
  • 18例(34%)患者输注后ETP-TM中位下降8.3%、均值下降12.8%,从1225(1071-1537)降至1124(812-1370 nM×min),p≤0.0001。
  • FFP显著改善INR和aPTT(p<0.0001),但仅少数患者INR/PT比值降至1.5以下。
  • 代偿期肝硬化、慢加急性肝衰竭、感染或休克患者对FFP的反应相似。

关键数值与推荐

  • FFP标准剂量,用于出血治疗或侵入性操作前,纳入标准为INR/PT比值≥1.5。
  • 主要终点ETP-TM改善,输注后仅提高5.7%。
  • 输注前94%患者ETP-TM正常或升高,低ETP-TM患者无出血。

临床怎么用

  • 肝硬化凝血障碍患者输注FFP对凝血酶生成的改善有限,应审慎评估指征。
  • 常规凝血指标改善不代表凝血功能全面恢复,需结合临床综合判断。
  • 以预防或治疗出血为目的的FFP输注可能无明确获益,且存在风险和费用。

局限性

  • 样本量较小(53例),可能影响结果的普遍性。
  • 未报告对照组或随机化设计,观察性研究存在混杂可能。
  • 原文未报告长期临床结局(如出血事件、死亡率)与FFP输注的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The efficacy of fresh frozen plasma (FFP) transfusion in enhancing thrombin generation in patients with cirrhosis and impaired conventional coagulation tests has not been sufficiently explored. Thus, we aimed to assess the effect of FFP transfusion on thrombin generation in these patients. METHODS: Fifty-three consecutive patients receiving a standard dose of FFP to treat bleeding and/or before invasive procedures - if international normalized ratio (INR)/prothrombin time (PT) ratio were ≥1.5 - were prospectively enrolled. The primary endpoint was the amelioration of endogenous thrombin potential (ETP) with thrombomodulin (ETP-TM) after transfusion, which corresponds to the total amount of generated thrombin. INR/PT ratio and activated partial thromboplastin time (aPTT) were also assessed before and after transfusion. RESULTS: FFP enhanced ETP-TM by 5.7%, from 973 (731-1,258) to 1,028 (885-1,343 nM × min; p = 0.019). Before transfusion, evidence of normal or high ETP-TM was found in 94% of patients, even in those with bacterial infections. Only 1 (1.9%) patient had ETP-TM values reverting to the normal range after transfusion. Notably, no patients with low ETP-TM had bleeding. The median decrease in ETP-TM was 8.3% and the mean was 12.8% in 18 (34%) patients after transfusion (from 1,225 [1,071-1,537] to 1,124 [812-1,370] nM × min; p ≤0.0001). Similar responses to FFP transfusion were observed in patients with compensated and acute decompensated cirrhosis, acute-on-chronic liver failure, infection or shock. FFP significantly ameliorated INR and aPTT values (p <0.0001), but in a minority of patients the values were reduced to less than the cut-off point of 1.5. CONCLUSIONS: FFP transfusion enhanced thrombin generation and ameliorated conventional coagulation tests to normal values in a limited number of patients, and slightly decreased thrombin generation in 34% of cases. LAY SUMMARY: Transfusion of fresh frozen plasma in patients with cirrhosis only slightly improves coagulation test values in a limited number of patients and even appears to worsen them in a third of cases. Transfusion for the purpose of preventing or treating bleeding events could cause inherent risks and costs without clear benefits.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rassi AB, d'Amico EA, Tripodi A, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. J Hepatol. 2019. PMID: 31536747. doi:10.1016/j.jhep.2019.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。